ESR1 and breast carcinoma: Used in treatment-naïve, ER+/EGFR+/HER2+ breast cancer patients and patients with HER2-positive advanced breast cancer that has progressed after previous treatment to Trastuzumab, anthracycline and taxane derived drugs.